Intermediate class of drugs has potential to affect cost and availability, GAO report says.
This article was originally published in The Tan Sheet
Executive Summary
PHARMACY-CLASS OF DRUGS HAS POTENTIAL TO AFFECT DRUG COSTS, AVAILABILITY, the General Accounting Office speculated in a report released on Aug. 24. The establishment of a third class of drugs in the U.S. "could affect the price and availability of drugs to consumers and might also alter the revenues or profits of both manufacturers and retailers," the GAO cautioned.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning